Aclaris Therapeutics (NASDAQ:ACRS) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

Several other equities analysts have also weighed in on ACRS. Craig Hallum initiated coverage on Aclaris Therapeutics in a research note on Friday, January 30th. They issued a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Friday, March 27th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Aclaris Therapeutics in a research note on Thursday, March 19th. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Aclaris Therapeutics in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Aclaris Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Trading Up 0.5%

NASDAQ:ACRS opened at $3.92 on Friday. Aclaris Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.89. The business’s 50-day moving average price is $3.53 and its two-hundred day moving average price is $3.00. The firm has a market capitalization of $472.75 million, a price-to-earnings ratio of -7.40 and a beta of 0.67.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $2.07 million. Sell-side analysts predict that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

Hedge funds have recently modified their holdings of the business. Three Bridge Wealth Advisors LLC acquired a new stake in shares of Aclaris Therapeutics during the third quarter worth about $1,358,000. JPMorgan Chase & Co. grew its holdings in shares of Aclaris Therapeutics by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 758,576 shares of the biotechnology company’s stock worth $1,441,000 after buying an additional 134,784 shares in the last quarter. AXQ Capital LP bought a new position in shares of Aclaris Therapeutics during the third quarter worth about $27,000. Squarepoint Ops LLC grew its holdings in shares of Aclaris Therapeutics by 11.9% during the second quarter. Squarepoint Ops LLC now owns 390,583 shares of the biotechnology company’s stock worth $555,000 after buying an additional 41,666 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new position in shares of Aclaris Therapeutics during the fourth quarter worth about $52,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.